Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Gains Approval For Generic EpiPen, Mylan Shares Flat
Mylan Rejects Teva Buyout Offer
How Mylan tried to keep Teva from selling a generic EpiPen
Teva's recall of U.S.-made drugs latest example of contamination fears in generic marketplace; report says Lilly, Pfizer and former Mylan plant in Morgantown have been cited in the past | WV News
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
$40B deal: Teva offers to buy Mylan
Teva makes $40B offer for Mylan
Generic Drugmakers Mylan and Teva Face Antitrust Complaint
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
Teva Offers to Buy Mylan for $40 Billion - WSJ
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Teva makes $40 billion offer for Mylan
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
